
Patrick Mcdonagh
The Neuro’s drug discovery initiative supports research by developing assays shared with the scientific community
In the past 40 years, the model of drug discovery used by the pharmaceutical industry, while proving successful for some applications, has produced very little for neurodegenerative diseases.
“We have to ask if there is a better way to find therapies that will modify the course of diseases, slowing or stopping them from progressing. While Open Science is not going to solve every problem, it will be a big part of the solution.”“Take Parkinson’s disease, for instance: there have been zero new disease modifying medications developed in the last 40 years, despite hundreds of millions of dollars being invested in research,” says Dr. Edward Fon, whose lab focuses on molecular and cellular research into Parkinson’s disease. “We have to ask if there is a better way to find therapies that will modify the course of diseases, slowing or stopping them from progressing. While Open Science is not going to solve every problem, it will be a big part of the solution.”
The Neuro’s drug discovery initiative aims to support research by developing assays that investigate different aspects of target cells and sharing these assays with colleagues around the world. The main vehicle for sharing assays is The Neuro’s Induced Pluripotent Stem Cell (iPSC) platform, developed recently with seed money generously donated by Sebastian van Berkom and Ghislaine Saucier.
“We can provide industry-standard assays researchers can use to test compounds,” says Thomas Durcan, another Parkinson’s researcher who manages the iPSC platform. “In collaboration with researchers at Université Laval, we reprogram blood cells from patients with neurological diseases into stem cells, and then transform the stem cells into the type of neural cells most impacted in neuropathology.”
This gives researchers the ability to compare normal and diseased states of the cells within one patient, which has long been possible for some diseases but is a novel advance for neurological research. The Centre for Drug Research and Development, a Canadian nonprofit organization that aims to speed the translation of discoveries into therapies, and the international Structural Genomics Consortium have both formed partnerships with the Tanenbaum Open Science Institute to use the iPSC platform.
“If we can identify potential compounds for targeting diseases such as Parkinson’s and share them so they can be screened and tested throughout the scientific community, we can accelerate the rate of discovery,” says Dr. Fon. “Other researchers can benefit from the resources we develop, and the chances of 100 laboratories finding something useful is much greater than that of one lab working alone. If we can come up with something leading to treatment for Parkinson’s disease, that would be an incredible payback.”
Learn more: Accelerating drug discovery with Open Science
The Latest on: Open Science
[google_news title=”” keyword=”Open Science” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Open Science
- A researcher who publishes a study every two days reveals the darker side of scienceon June 4, 2023 at 8:59 am
Spain’s most prolific scientific academic — meat expert José Manuel Lorenzo — put his name on 176 papers last year, exposing an underworld of shady practices ...
- Open science resources for Parkinson’s researchon June 1, 2023 at 3:51 pm
MJFF has so far invested more than US$1.75 billion into global research and open science practices. The organisation provides scientists with resources: funding, data, bio-samples, laboratory ...
- Open Hardware For Open Science – Interview With Charles Fracchiaon May 29, 2023 at 5:00 pm
Open Science has been a long-standing ideal for many researchers and practitioners around the world. It advocates the open sharing of scientific research, data, processes, and tools and ...
- Accelerating the discovery of new treatments for neurological disorders through Open Scienceon May 26, 2023 at 2:02 am
To meet the global challenge of neurological disorders, The Neuro (Montreal Neurological Institute-Hospital) has radically transformed the approach to brain science. As an Open Science institution ...
- Open Science Platform to focus on strengthening open science ecosystemon May 16, 2023 at 7:06 am
KUALA LUMPUR: The Open Science Platform (MOSP) that was launched today (May 16) will focus on strengthening the open science ecosystem in the country, says Chang Lih Kang. The Science, Technology ...
- Malaysia Open Science Platform: A Dream or A Reality?on May 15, 2023 at 5:00 pm
Read on to find out more. In recent years, many international organisations advocate and promote open science principles. Open science stresses on making scientific research accessible to all ...
- Open science licenseson May 9, 2023 at 8:11 am
Guidelines like the Panton Principles for data sharing give recommendations for licenses that are appropriate for practicing open science. A good guideline is to use a license that places the fewest ...
- Starting to practice Open Scienceon May 9, 2023 at 8:10 am
Open access (free access without request) publications are an easy way to start practicing open science. There are two type of open access, green and gold. Both are open, and both work to give folks ...
- Bioinformatics, data and the value of open scienceon April 25, 2023 at 5:00 pm
She mentions the Lero Open Source and Open Science Programme Office as an exciting recent initiative launched to promote and support open science. Earlier this year, Lero was awarded a European ...
- Roundtable on Aligning Incentives for Open Scienceon November 1, 2022 at 6:14 am
The Roundtable on Aligning Incentives for Open Science of the National Academies of Sciences, Engineering, and Medicine brings together stakeholders to discuss the effectiveness of current incentives ...
via Bing News